J&J’s Carvykti and BMS’ Abecma Win FDA Approvals for Earlier Use in Multiple Myeloma
XTalks
APRIL 11, 2024
In last month’s call, Legend CEO Ying Huang, PhD, shared that the partners are aiming to increase manufacturing capacity at their New Jersey plant. 2seventy has been used to the struggles ever since it spun out of gene therapy biotech bluebird bio. In addition, the companies are also gunning for a first-line setting approval.
52 
Let's personalize your content